Embryosafe® PGT-A *next*

eurofins | Genoma

Embryosafe® PGT-A *next*

eurofins | Genoma

Polyploid embryos, characterized by an abnormal number of chromosomes, are relatively rare.
Despite their low incidence, triploidies are estimated to account for about **2% of natural pregnancies** and are found in **15% of spontaneous pregnancy losses with chromosomal abnormalities.** On the other hand, it may happen that embryos resulting from abnormal fertilization (0, 1, 2.1/3PN) have **ploidy rescue.**

PGT-A *next* enables the assessment of the **embryo's ploidy status**, aiding in the identification and selection of embryos with the highest likelihood of **successful implantation** and a **healthy pregnancy**.



When PGT-A *next* should be considered:

- Advanced maternal age
- Male infertility factors (e.g., high diploidy rates in sperm)
- Repeated IVF failures
- Available embryos derived from abnormally fertilized oocytes
- Previous pregnancy losses
- History of chromosomal abnormalities

Embryosafe® PGT-A *next*

eurofins | Genoma

PGT-A *next* combines the **Whole Genome Sequencing (low pass)** and the analysis of hundreds of **Single Nucleotide Polymorphisms (SNPs)** to improve the clinical utility of Preimplantation Genetic Testing for infertile couples.

NGS - Whole Genome Sequencing (low pass)

NGS - SNPs Targeted Sequencing

1 PGT-A

For the selection of **euploid embryos**, which may have higher chances of implantation and successful pregnancies.

2 Ploidy detection

For the **identification of polyploid embryos** and the **rescue of diploid embryos** from those morphologically identified as 0, 1 and 2.1/3PN.



3 DNA Fingerprinting

For the **genetic profiling** of the embryo to ensure that all embryos from the same patients are **genetically related**.



Embryosafe® PGT-A *next*

eurofins | Genoma

Beyond traditional aneuploidy testing.
Our analysis extensively explores the genetic characteristics of the embryo, providing a more thorough understanding of its genetic profile.

BETTER RESULTS

With PGT-A *next* is possible to better identify optimal embryos for transfer, **reducing the risk of miscarriage** due to previously undetected abnormalities and **boosting the odds of a successful pregnancy**.

ADDITIONAL CHANCES

Ploidy assessment helps to **better identify diploid embryos**, preventing the unnecessary disposal of potentially viable embryos.

IMPROVED SAFETY

DNA fingerprinting significantly reduces patient anxiety and can be conducted without needing additional samples, but simply **comparing other embryos from the same patients**.

CERTIFIED QUALITY

Eurofins Genoma is Accredited according to **UNI EN ISO 15189:2013** for the discipline of Medical Genetics for the PGT-A examination.
It participates in **External Quality Assessment** with GenQA for the evaluation of the accuracy of results.

Embryosafe® PGT-A *next*

eurofins | Genoma



*Please note: To request PGT-A *next*, select 'PGT-A + Poliploidy Panel' on the TRF

Embryosafe® **PGT-A** *next*

Genetic counselling is available before and after testing

info.genoma@ctit.eurofinseu.com
Customer Service: **0039 06 164 161 500**

eurofins | Genoma

COMPANY WITH QUALITY SYSTEM CERTIFIED BY DNV
ISO 9001

ROME
Legal Office and Molecular Biology Laboratory
Via Castel Giubileo, 11
00138

Medical Genetics And Molecular Diagnostics Laboratory Withdrawals And Consultations
Via Castel Giubileo, 62
00138

MILAN
Medical Genetics Laboratory and Medical Offices
Via Enrico Cialdini, 16
(Affori Centre) 20161

MODENA
Laboratory and Medical Offices
Via Bellinzona, 47/D
41124

FLORENCE
Laboratory and Medical Offices
Via Cavour, 168r
5012 1